4D Molecular Therapeutics Inc

NASDAQ:FDMT   10:07:41 AM EDT
30.91
-1.06 (-3.32%)
Earnings Announcements

4D Molecular Therapeutics Reports Financial Results For The Year Ended December 31, 2020 And Provides Operational Highlights

Published: 03/25/2021 21:44 GMT
4D Molecular Therapeutics Inc (FDMT) - 4d Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights.
4d Molecular Therapeutics Inc - Cash and Cash Equivalents of Approximately $277 Million As of Dec 31, 2020.4d Molecular Therapeutics Inc - Expect Cash and Cash Equivalents to Be Sufficient to Fund Operations Into Mid-2023.
Revenue is expected to be $0.18 Million
Adjusted EPS is expected to be -$0.81

Next Quarter Revenue Guidance is expected to be $0.18 Million
Next Quarter EPS Guidance is expected to be -$0.96

More details on our Analysts Page.